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Abstract: The treatment of multiple sclerosis (MS) has changed over the last 20 years.
All immunotherapeutic drugs target relapsing remitting MS (RRMS) and it still remains a medical
challenge in MS to develop a treatment for progressive forms. The most common injectable
disease-modifying therapies in RRMS include β-interferons 1a or 1b and glatiramer acetate. However,
one of the major challenges of injectable disease-modifying therapies has been poor treatment
adherence with approximately 50% of patients discontinuing the therapy within the first year. Herein,
we go back to the basics to understand the immunopathophysiology of MS to gain insights in the
development of new improved drug treatments. We present current disease-modifying therapies
(interferons, glatiramer acetate, dimethyl fumarate, teriflunomide, fingolimod, mitoxantrone),
humanized monoclonal antibodies (natalizumab, ofatumumab, ocrelizumab, alemtuzumab,
daclizumab) and emerging immune modulating approaches (stem cells, DNA vaccines, nanoparticles,
altered peptide ligands) for the treatment of MS.
Keywords: multiple sclerosis; immunotherapy; drug delivery; vaccine
1. Introduction
In the early 1900s, only a few cases of multiple sclerosis (MS) were reported, which quickly became
a common occurrence for admission to neurological wards. Today, MS accounts over 2.5 million
affected individuals with an estimated cost of US$2–3 billion per annum [1]. The distribution of MS
varies according to geographic location. For example, the further north or south from the equator the
higher the prevalence of MS; countries that lie on the equator have extremely low prevalence compared
to Scotland, Norway, and Canada. The prevalence of MS has increased progressively over time with
30/100,000 diagnosed in 2008 to 33/100,000 diagnosed in 2013 globally. In fact, in a Norwegian cohort
over 53 years (1961–2014), the prevalence increased from 20 to 203/100,000 and the incidence increased
from 1.9 to 8/100,000 [2]. It is possible that the increase in prevalence is due to improved diagnostic
procedures and reporting and changes in lifestyle (lack of vitamin D and increased smoking) [1].
MS is commonly diagnosed between 20 years and 40 years of age although it can affect younger
and older individuals [3], and most commonly affects those with a genetic predisposition (major
histocompatibility complex (MHC) class II phenotype, human leukocyte antigen (HLA)-DR2 and
HLA-DR4 most commonly affected). In fact, the incidence of MS is increased 10-fold in monozygotic
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twins as compared to siblings of patients with MS [4–6]. In addition, viral infections can trigger disease
where parts of the virus mimics that of the myelin sheath [7]. Although usually not life-shortening,
MS is a chronic neurological disease often interfering with life and career plans of an individual [8].
MS is categorized into 4 distinct types, primarily based on its clinical course, which are
characterized by increasing severity: (a) Relapsing/remitting MS (RRMS), the most common form,
affecting 85% of all MS patients which involves relapses followed by remission; (b) secondary
progressive MS (SPMS), which develops over time following diagnosis of RRMS; (c) primary
progressive MS (PPMS) affecting 8–10% of patients, noted as gradual continuous neurologic
deterioration; and (d) progressive relapsing MS (PRMS) the least common form (<5%), which is
similar to PPMS but with overlapping relapses [9–11]. MS leads to a wide range of symptoms with
various severity involving different parts of the body. MS diagnosis is mainly clinically based however,
magnetic resonance imaging (MRI) assists in diagnosis [12]. As such, examination of the cerebrospinal
fluid (CSF) and visual induced potentials with MRI can assist in confirming the clinical suspicion of
MS [12,13]. MS symptoms and disease progression are varied, with some individuals experiencing
little disability while most (up to 60%) require a wheelchair 20 years from diagnosis [9].
Although treatments against MS are able to decrease the relapse rate in RRMS, the prevention
of long-term effects remains a problem; medications for progressive forms of MS are also limited
in their efficacy. Hence, new improved drugs are required to effectively treat MS. One of the major
pathophysiological mechanisms of MS involves autoreactive T cells, primarily T helper (Th)-1 CD4+ T
cells and Th17 cells leading to cytokine secretion and activation of an inflammatory cascade resulting in
demyelination within the brain and spinal cord and axonal damage; autoreactive antibodies cannot be
discounted. Indeed, MS is generally known as a chronic autoimmune disorder of the central nervous
system (CNS) [14,15]. MS causes breakdown of the blood brain barrier (BBB) leading to migration
of immune cells (macrophages, T cells, B cells) and secretion of pro-inflammatory cytokines and
chemokines [16] which induces inflammation, formation of sclerotic plaques (lesions), demyelination
and neurodegeneration [17]. MS lesions may form in any location of the CNS white matter or in
grey matter, often leading to physical disability and sometimes, decline in cognitive ability [16,18].
It is therefore, conceivable to target immune cells and their products in order to prevent tissue
damage by modulating inflammation [9,19] while reducing potential side effects such as global
immunosuppression [6,19,20]. The major constituents of the myelin sheath in which autoreactive T cells
and antibodies recognize, include, myelin basic protein (MBP), myelin oligodendrocyte glycoprotein
(MOG) and proteolipid protein (PLP).
2. Immunopathophysiology of MS
The brain has primarily been considered to be an organ which is highly immune-advantaged,
although a number of studies have challenged this [6]. In the last 10 years an important shift has
surfaced in MS research, suggesting that MS is not just a disease of the immune system, but equally
involves factors contributed by the CNS [21,22]. Immune cells residing in the CNS get activated
following damage to CNS tissue; notably microglial cells whereby they upregulate MHC class I and II
molecules and cell surface co-stimulatory molecules and secrete cytokines and chemokines, paving
entry for T (CD4 and CD8) cells, B cells, monocytes, macrophages and dendritic (DC)-like cells into
CNS lesions [6]. Infiltrating immune cells secrete pro-inflammatory cytokines, nitric oxide, and matrix
metalloproteinases [23,24], leading to destruction of the myelin sheath.
It has been generally accepted that chronic inflammation is the hallmark of neurodegenerative
diseases, such as MS, Alzheimer’s disease and Parkinson’s disease [6,7]. Myelin-reactive auto-T cells
cross the BBB [19] and their migration into the CNS consequently initiates an inflammatory cascade
followed by demyelination of the CNS and axonal damage. These cells reside in the perivenous
demyelinating lesions which generate distinct inflammatory demyelinated plaques situated within
the white matter [25]. MS lesions appear in the white matter inside the visual neuron, basal ganglia,
brain stem and spinal cord [26]. White matter cells transmit neural signals from grey matter, where
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information is gathered, and transferred to the rest of the body [25,27]. MS involves 2 main steps,
(i) myelin sheath damage resulting in formation of lesions in the CNS and (ii) inflammation, which
together destroy the neuron tissue [25,28]. In MS, damage of oligodendrocytes and destruction of
myelin sheath leads to breakdown of the nerve axon and loss of neuronal function [28]. Demyelination
increases the inflammatory activation processes leading to damage of BBB and stimulation of
macrophage activation and oxidative stress pathways [29]. The white matter lesions include myelin
breakdown together with infiltration of monocytes, B cells, T cells and DC [30]. Microglia and
macrophages are the main innate immune cells present in MS lesions where they either act together
with T and B cells, or directly cause neuroinflammatory tissue damage [31]. Cells involved in the
inflammatory process include those that are both in the innate and adaptive immune systems and are
described below (Figure 1).
Brain Sci. 2017, 7, 78    3 of 26 
information is gathered, and transferred to the rest of the body [25,27]. MS involves 2 main steps, (i) 
yelin  sheath damage  resulting  in  formation of  lesions  in  the CNS and  (ii)  inflam ation, which 
together destroy  the neuron  tissue [25,28].  In  S,  a age of oligodendrocytes and  estruction of 
myelin  sheath  leads  to  breakdown  of  the  nerve  axon  and  loss  of  euronal  function  [28]. 
D myelinatio   increases  the  infl mmatory  activation  processes  le ding  to  damage  of  BBB  and 
stimulation of macrophage activation and oxidative  tress pathways [29]. The white matter l sions 
include myelin  breakdow   together with  infiltra ion  of monocyt s, B  cells, T  cells  and DC  [30]. 
Microglia and macrophages  re  the main  innate  immu e  cells present  in MS  lesions where  they 
either act together with T and B cells, or directly cause neuroinflam atory tissue damage [31]. Cells 
involved in the inflammatory process include those that are both in the innate and adaptive immune 
systems and are described below (Figure 1). 
 
Figure 1. The immunological complexity of the immune/cytokine network in multiple sclerosis. 
2.1. Natural Killer T (NKT) Cells 
NKT  cells  share  properties  of  both  T  cells  and NK  cells  and  recognize  glycolipid  antigens 
presented  in complex with  the MHC class  I‐like molecule, CD1d. Two subsets of NKT cells have 
been identified (type I, invariant NKT (iNKT) cells and type II, variant NKT (vNKT) cells) and are 
implicated  in  the pathogenesis  of MS  in humans  and  in  the murine model  of MS,  experimental 
autoimmune  encephalomyelitis  (EME).  iNKT  cells  express  cell  surface markers  characteristic  of 
activated or memory T cells (CD25, CD44, CD69) with the majority being CD4+ as well as markers 
characteristic of NK cells (NK1.1 or CD161, Ly49). Following activation of iNKT cells (via binding to 
α‐GalCer‐CD1d complex) an array of cytokines  is secreted  that are associated with both pro‐ and 
anti‐inflammatory  immune  responses and play a  role  in both  innate and acquired  immunity. As 
such, iNKT cells, (i) secrete interleukin (IL)‐4 and IL‐13 which stimulate CD4+ T cells to differentiate 
into anti‐inflammatory Th2 cells (IL‐4, IL‐10 producers) which inhibit Th17, Th1, CD8+ T cells in the 
Figure 1. The im unological complexity of t i cytokine network in multiple sclerosis.
2.1. Natural Killer T (NKT) Cells
NKT cells share properties of both T cells and NK cells and recognize glycolipid antigens presented
in complex with the MHC class I-like molecule, CD1d. Two subsets of NKT cells have been identified
(type I, invariant NKT (iNKT) cells and type II, variant NKT (vNKT) cells) and are implicated in
the pathogenesis of MS in humans and in the murine model of MS, experimental autoimmune
encephalomyelitis (EME). iNKT cells express cell surface markers characteristic of activated or memory
T cells (CD25, CD44, CD69) with the majority being CD4+ as well as markers characteristic of NK cells
(NK1.1 or CD161, Ly49). Following activation of iNKT cells (via binding to α-GalCer-CD1d complex)
an array of cytokines is secreted that are associated with both pro- and anti-inflammatory immune
responses and play a role in both innate and acquired immunity. As such, iNKT cells, (i) secrete
interleukin (IL)-4 and IL-13 which stimulate CD4+ T cells to differentiate into anti-inflammatory
Th2 cells (IL-4, IL-10 producers) which inhibit Th17, Th1, CD8+ T cells in the CNS; (ii) secrete IL-2
Brain Sci. 2017, 7, 78 4 of 27
and tumor growth factor (TGF)-beta which stimulate the production of T regulatory (Treg) cells
(IL-10, TGF-beta producers) which inhibit Th17, Th1 and CD8+ T cells in the CNS; and (iii) secrete
IL-4, IL-10, IL-13, interferon (IFN)-gamma and GM-CSF which activate suppressive myeloid derived
suppressor cells (MDCs), DC and macrophages which in turn secrete IL-10 to activate Treg cells
and suppress Th17, Th1 and CD8+ T cells in the CNS [32]. Due to the pleiotropic properties of
iNKT cells, they play a role in protecting the host against pathogens, tumors, autoimmunity and are
involved in tissue rejection, ischemia reperfusion injury and obesity related diabetes [32]; deficiency or
dysfunction of iNKT cells has been shown to be linked to the development of autoimmune diseases.
Indeed, iNKT cell numbers are decreased in patients with MS [32] and are restored in patients in
remission [33]. Analysis of iNKT cells in MS patients in remission showed a Th2 cytokine profile,
suggesting an immunoregulatory effect of iNKT cells in MS [34]. Similarly, in the EAE mouse model,
protection of EAE development is associated with high levels of iNKT cells and suppression of Th1
and Th17 cells [35]. Interestingly, injections of α-Galactosylceramide (α-GalCer), and analogues
thereof, have potent activities in protecting mice against, cancer, infections, inflammatory conditions
and autoimmune disorders. Hence, it is possible to develop iNKT cell based modulating therapies
against MS [36,37]. Like iNKT cells, variant NKT (vNKT) cells also share properties of both T cells
(CD4+) and NK cells (NK1.1) and recognize β-linked glycolipid antigens in complex with CD1d.
They are less common in mice compared to iNKT cells but are more abundant in humans. Of interest,
vNKT cells recognize the self-glycolipid, sulphatide, which is abundantly expressed within the myelin
sheath suggesting a role in MS although not yet established [38]. Likewise, vNKT cells recognizing
sulphatide self-myelin ligand are present in high levels in mice with EAE suggesting their role in
disease progression [38].
2.2. Mucosal-Associated Invariant T (MAIT) Cells
MAIT cells are a subset of T cells of the innate immune system to defend against microbial
infections. They are present in the liver, lungs, mucosa and blood and make up to 25% of CD8
T cells in healthy individuals; they also support adaptive immune responses in that they have a
memory like phenotype [39]. The MHC class I-like molecule, MRI, presents microbial antigens and
vitamin B metabolites to MAIT cells, leading to their activation [39,40]. However, MAIT cells have also
been implicated in autoimmune diseases such as MS, inflammatory bowel disease and rheumatoid
arthritis where they are often noted at the site of autoimmune attack. Recently, it was reported that
in MS, MAIT cells are highly present at the sites of demyelination and secrete pro-inflammatory
Th1 cytokines (IFN-gamma and TNF-alpha) and activate Th17 cells (IL-17 and IL-22 cytokines) [22];
the major cytokines in the pathogenesis of chronic inflammatory and autoimmune diseases. In addition,
MAIT cell have been noted in white matter inflammatory lesions [41] as well as transcription over
expression of MR1 in MS lesions. Conversely, it has been reported that MAIT cells are decreased
in blood of patients with RRMS [42]. It is not clear whether MAIT cells exert a protective or a
non-protective role, thus a better understanding of how MAIT cells are involved in MS and of their
interactions would aid in a better understanding of the pathogenesis of MS and development of
therapeutic strategies.
2.3. Regulatory T Cells (Tregs)
Regulatory T cells (Tregs; originally known as suppressor T cells) are a subset of CD4+ T cells that
modulate immunity, maintain tolerance against self-antigens and prevent autoimmunity. Tregs are
primarily characterized as Foxp3+CD25+CD4+ and are anti-inflammatory (secrete IL-10). One of the
first evidence of the role of Treg cells in MS was in mouse EAE models, where adoptive transfer of Treg
cells from control mice into MOG or PLP induced EAE mice prevented the onset and progression of
EAE [43,44]. Adoptive transfer of Treg cells recovering from EAE into MOG-induced active EAE mice
resulted in resolution of EAE [45]. In addition, induction of Treg cells by estradiol or by monocytes
under glatiramer acetate treatment reduced clinical signs of MOG-EAE [46,47]. Furthermore, injection
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anti-CD28 monoclonal antibody in Lewis rats results in Treg cell expansion and reduction in EAE
disease severity [48]. Interestingly, injection of anti-CD25 monoclonal antibody, which blocks the effects
of Treg cells into C57BL/6 mice increased susceptibility to EAE induction [45]. In patients with MS
however, the frequency of Foxp3+CD25+CD4+ Treg cells does not differ to those in healthy individuals,
although the function of such cells are impaired (maturation and migration) [49]. In addition, mRNA
and protein levels of Foxp3 are impaired in Treg cells of patients with MS especially in RRMS and are
normalized during SPMS [49]. Hence, impaired functionality of Treg cells is primarily observed in
the early stages of MS but not in their chronic stage, suggesting a causative role [50]. Further studies
of Treg cells in MS may aid in the understanding for why tolerance against self-antigens is broken,
leading to disease. However, it is not clear whether the impaired function of Treg cells is a direct cause
of MS or whether such impairment is a general outcome for all autoimmune disorders.
2.4. Macrophages and Microglia
Macrophages are divided into M1 or M2 based on their pro- or anti-inflammatory cytokine
secretion phenotype [51]. M1 macrophage phenotype of mice (F4/80+CD11b+CD11c+iNOS+)
and human (CD40+CD86+CD64+CD32+) is induced in the presence of interferon (IFN)-gamma
and/or toll-like receptor (TLR) ligands such as lipopolysaccharide (LPS). M1 macrophages are
pro-inflammatory and primarily secrete IL-1, IL-6, IL-12, TNF-alpha, iNOS and MCP-1 [51].
In general, they stimulate adaptive immune responses. The M2 macrophage phenotype of mice
(F4/80+CD11c−CD301+Arg1+CD206+) and humans (CD163+CD206+) is induced in the presence of
IL-4, IL-10, IL-13 and Arg1 that blocks iNOS activity [51]. M2 macrophages are anti-inflammatory
and primarily secrete IL-1 receptor antagonist, IL-4, IL-10, transforming growth factor (TGF)-beta1.
Macrophages play a crucial role in the pathogenesis of MS. In fact, in active demyelinating and early
re-myelinating lesions, macrophages are highly present compared to inactive, demyelinated or late
re-myelinated lesions [52]. However, a distinction of M1 vs M2 macrophages in human brain tissues
is not so clear, with both M1 macrophages and an intermediate subtype (M1/M2, CD40+CD206+)
being present [53]. Like macrophages, microglia cells are divided into M1- and M2-polarized microglia
cells. M1 microglia cells are pro-inflammatory and express CD40, CD74, CD86 and CCR7, whereas,
M2 microglia cells are anti-inflammatory and express mannose receptor (CD206) and CCL22. In MS
brain lesions however, like macrophages, an intermediate microglia phenotype is present expressing
CD40, CD74, CD86 and CCL22 but not CD206 markers [54]. Interestingly, in an EAE model it was
shown that suppression of CCL22 decreased M1 macrophage accumulation in the CNS, thus therapies
designed to suppress CCL22 have the potential to decrease demyelination and progression of disease.
In addition, in mice M1 microglia cells have been found to switch to M2 microglia cells during
remyelination, hence M2 polarization is necessary for efficient remyelination [55]. Indeed, fasudil
(a selective Rho kinase inhibitor), injected into EAE bearing mice shifted M1 to M2 macrophages and
ameliorated the clinical severity of EAE [56].
2.5. T Helper Cells
CD4 T cells or T helper (Th) cells, recognize short 9–17 amino acid peptides presented on the
surface of antigen presenting cells (APC) in complex with MHC class II. CD4 T cells differentiate into
distinct Th cells depending on the cytokine secretion profiles [57]. (i) Th1 cells are pro-inflammatory
and produce high levels of IL-2, IL-12, TNF-alpha and IFN-gamma; (ii) Th2 cells are anti-inflammatory
and secrete IL-4, IL-5, IL-6, IL-10, IL-13, IL-25; (iii) Th17 cells are pro-inflammatory and secrete high
levels of IL-17A, IL-17F, IL-21, IL-22, IL-24, IL-26 and low levels of IL-9 and IFN-gamma; (iv) Th22 cells
which are a combination of Th1, Th2, Th17 phenotype and secrete IL-13, IL-22 and TNF-alpha and
(v) the newest addition to the Th subset, Th9, was identified for its potent secretion of IL-9. Th1, Th9,
Th17 cells are key contributors to MS by increasing inflammation within the milieu of the myelin site.
Th1 cells and their pro-inflammatory cytokine products are present in high levels within the
demyelinating axon and CNS lesions of humans and in MOG, PLP or MBP induced EAE in mice.
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Th1 cells recognize MOG, PLP and MBP peptide epitopes presented in the context of MHC class
II, HLA-DRB1*1501 (HLA-DR2, HLA-DR15) and HLA-DRB1*04 (HLA-DR4) alleles. As a result
CD4 T cells become activated, cross the blood brain barrier and induce CNS autoimmunity. Some
drug therapeutics target the MHC class II-peptide-T cell receptor (TCR) complex in an attempt to
modulate or divert Th1 responses to therapeutic Th2 responses. Indeed, it was recently shown that
dimethyl fumarate (DMF) injection in RRMS patients reduced Th1, Th17 and CD8 T cells and increased
Th2 cells; this resulted in high levels of IL-4 and decreased levels of IFN-gamma and IL-17 [58].
In addition, we have shown that mannan conjugation of self-MBP, PLP or MOG native peptides or
altered peptide ligands, are able to divert Th1 responses to Th2 responses in human PBMC from MS
patients, in immunized mouse spleen cells and are able to ameliorate EAE in mice [59–73]. The role
of Th9 cells in MS is not as clear although in mice, IL-9 and Th9 cells induce EAE and inflammation
and IL-9 knockout mice are protected from developing EAE [74]. Th17 cells play a crucial role in the
pathogenesis of MS in both mice and humans by inducing an inflammatory milieu. In fact, IL-17A is
present at high levels in CNS lesions, cerebrospinal fluid and in the serum of patients with MS [75].
Th17 cells express high levels of CCR6 which binds to the ligand CCL20 on vascular endothelial cells,
enabling their entry through the blood brain barrier where they secrete pro-inflammatory cytokines
including IL-17A. In addition, IL-17 interferes with the remyelination process. Of interest, anti-IL-17A
humanized neutralizing monoclonal antibody (AIN457 or Secukinumab) injected in patients with MS
showed reduction of lesions compared to placebo-treated control subjects [75]. In addition, Th22 cells
are highly present in the peripheral blood and cerebral spinal fluid of patients with active RRMS [76],
and IL-22 mRNA and Th22 cells are increased in relapsing MS compared to remitting MS patients [77].
Furthermore, Th22 cells specifically recognize MBP and are resistant to IFN-beta therapy [76].
IL-27, a member of the IL-6/IL-12 cytokine family, is secreted by macrophages, dendritic cells and
microglia cells, with pleiotropic roles in immunomodulation being either pro- or anti-inflammatory.
IL-27 also stimulates or inhibits T cell differentiation. Th1 cells are induced by IL-27 whereas Th2,
Th17 and Treg cells are inhibited by IL-27. In addition, Tr1 cells a specialized subset of T cells which
secrete IL-10 are induced in the presence of IL-27 [78]. In 40 patients with RRMS, circulating plasma
IL-27 levels were significantly higher compared to healthy control subjects [79]. Likewise, IL-27 and
IL-27R are elevated in post-mortem MS brain lesions compared to non-MS control brains. Macrophages
and microglia were identified to be the source of IL-27 and triggering infiltration of CD4 and CD8 T
cells [80]. In addition, the effects of IL-27 on microglia cells showed that nitric oxide, TNF-alpha
and IL-6 were secreted, promoting Th1 polarization, suggestive that IL-27 enhances microglia
neuroinflammation [81]. Hence, suppressing IL-27 may be a strategy to modulate inflammatory
responses in patients with MS.
2.6. CD8 T Cells
Classical CD8 T cells or cytotoxic T cells (Tc1 cells), recognize short antigenic 7-9-mer peptide
epitopes presented on the surface of APC in complex with MHC class I. In MS there is a genetic
association with HLA-A3 [82]; HLA-A2 has been shown to reduce the risk of MS in individuals
that also express MHC class II, HLA-DRB1*1501. The antigen specificity of CD8 Tc1 cells isolated
from patients with MS, has been suggested to be against MOG, MBP and PLP with cytolytic activity
against neuronal cells in vitro [83] although their pathogenic role in MS is still not clear. More recently
other subsets of CD8 T cells have been identified and are grouped into different subsets based on
their cytokine profile. In as such, classical Tc1 cells secrete IFN-gamma, Tc2 secrete IL-4, Tc10 secrete
IL-10, Tc17 secrete IL-17, Tc21 secrete IL-21, Tc22 secrete IL-22 and another subset is characterized
by secreting TNF-alpha. In MS, regardless of the stage and activity of disease CD8 T cells are noted
in high numbers, much higher than CD4 T cells at a ratio of 10:1 CD8:CD4 T cells. MHC class I
is highly expressed within MS lesions and astrocytes, oligodendrocytes, neurons in addition to the
classical APC, DCs and macrophages. In fact, CD8 T cells are found in great abundance within CNS
tissues and cerebrospinal fluid of patients with MS. CD8 T cells present in both acute and chronic
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MS lesions secrete high levels of IL-17 (classed as, Tc17 CD8 T cells) [84]. Tc17 cells secrete IL-17 and
TNF-alpha and low IFN-gamma and are negative for granzyme B, perforin and cytolytic activity unlike
the classical CD8 Tc1 cells. In peripheral blood of patients with SPMS and RRMS elevated levels of
Tc1 and Tc17 cells are noted as well as a high percentage of TNF-alpha secreting CD8 T cells [85];
Tc21 cells are increased in the remission phase of RRMS compared to SPMS. In addition, higher levels
of CD8+IFN-gamma+TNF-alpha+IL-17+ T cells in the relapsing phase of RRMS compared to remission
phase, SPMS and controls [85]. It is clear that CD8 T cells contribute to the pathogenesis of MS, and it
is important to understand how such cells escape T cell tolerance and induce CNS autoimmunity in
order to design and develop new therapeutics against MS.
2.7. B Cells
Although there is a presence of T cells in MS plaques, B cells also contribute to the pathogenesis of
MS where they secrete autoantibodies and cytokines and being APC they activate T cells. In patients
with MS the presence of oligoclonal bands (OCB) in cerebrospinal fluid and brain parenchyma is a
consistent finding in over 95% of patients. OCB is a product of clonally expanded B cells and IgG
synthesis. In MS plaques plasma cells are noted in large numbers where antigen uptake, processing
and presentation takes place as well as synthesis of IgG. Interestingly, over 50 antibodies isolated
from cerebrospinal fluid from patients with MS did not react to MBP, PLP or MOG [86] but some
groups reporting that they bind to intracellular proteins such as, MKNK1/2, FAM84A, AKAP12A
and glial potassium channel KIR4.1, or, against intracellular lipid determinants [87,88]. Moreover,
anti-MOG autoantibodies is a hallmark of childhood MS as well as in some patients with neuromyelitis
optical spectrum disorder. It is clear, that abnormal activation of B cells within the CNS of patients
with MS, suggests that B cells play a role in the pathophysiology of the disease. Further studies are
required to ascertain whether B cell depletion is able to restore immune function and hence, be used as
a therapeutic target against MS.
2.8. Dendritic Cells
DC are professional APC which process and present antigenic peptide epitopes on their surface
in complex with MHC class I or class II, resulting in CD4 or CD8 T cell stimulation respectively.
Even though MS is generally associated with predominant auto-reactive T cells, emerging evidence
indicates that DCs play an important role in the pathophysiology of MS, primarily due to their T cell
activating and cytokine secreting properties. Following activation of DCs in the periphery, T cells
specific to myelin epitopes are activated inducing pro-inflammatory cytokines aiding their entry
through the BBB into the CNS. In the CNS resident APC and T cells are further activated leading to
demyelination and motor deficits. In patients with MS, DCs are abundantly present within inflamed
lesions, cerebrospinal fluid and in the circulation and produce high levels of TNF-alpha, IFN-gamma
and IL-6 [89]. In addition, the expression of co-stimulatory molecules, CD40 and CD80 on DCs
are increased in RRMS and SPMS patients, suggesting an activated pro-inflammatory state of DCs,
hence their contributing role in the pathogenesis of MS.
2.9. Myeloid Derived Suppressor Cells
Myeloid-derived suppressor cells (MDSC) are myeloid progenitors, the same lineage to that of
macrophages, DC and neutrophils. However, MDSC have strong immunosuppressive properties rather
than immune-stimulatory properties as noted with macrophages, DC and neutrophils [90]. Their major
role is in tumor development and chronic inflammation having immune suppressive effects [90].
As such, it was recently shown following MBP1–11 peptide immunization in mice, that MDSCs were
increased adopting a suppressive phenotype, inhibiting the activation of CD4+ T cells via arginase-1
and inducible nitric oxide synthase; such approach inhibited the development of EAE in mice [91].
In addition, MDSC secrete inhibitory enzyme indoleamine 2,3-dioxygenase and Th2 cytokine, IL-10 [92].
It is not clear whether the number of MDSCs are reduced or whether their functionality is altered
Brain Sci. 2017, 7, 78 8 of 27
in patients with MS, leading to the failure of MDSCs to suppress autoimmune T cells, as a result of
disease progression. The use of ex vivo cultured MDSCs could be a viable strategy to develop new
improved treatments against MS.
3. Current Drug Therapies for Multiple Sclerosis
The majority of the treatments for MS are long term mainly suppressing the immune system
however, such immune-suppressants pose increased risks for infections and cancer [27]. Alternative
treatment options involve disease-modifying therapies such as, interferons, glatiramer acetate,
monoclonal antibodies and sphingosine-1-phosphate receptor modulators (Table 1, Figure 2). These
therapies have dramatically reduced the number of attacks and decreased disease progression. In fact,
interferons are effective in the early relapsing phases of MS but not in the advanced phases of the
disease [27]. Ultimately, induction of tolerance against self-antigens and re-establishing immune
homeostasis can effectively “cure” the disease; such strategies have been the focus of recent research.
Table 1. Disease-modifying drugs available to patients with RRMS.
Drug Brand Dose Number of ofInjections, Route Actions
IFN-β1a Avonex
®
7.5 mg 1st dose
1/week, i.m
Balances pro- and
anti-inflammatory cytokines
15 mg 2nd dose Decreases Th17 cells
22.5 mg 3rd dose
Decreases IL-1730 mg all subsequent doses
Rebif® 22 mg or 44 mg 3/week, s.c
IFN-β1b Betaseron
® 62.5 mg and increase over
6 weeks to 250 mg 1/2 days, s.c
Extavia®
62.5 mg and increase over
6 weeks to 250 mg 1/2 days, s.c
pegIFN-β1a Plegridy
® 63 mg 1st dose 1/2 weeks, s.c95 mg 2nd dose
125 mg all subsequent doses
Glatiramer acetate,
EKAY
Copaxone® 20 mg or 40 mg
1/day, s.c Blocks pMHC
3/week, s.c
Dimethyl fumarate Tecfidera® 240 mg 2–3/day, oral Anti-inflammatory Anti-oxidative stress
Teriflunomide Aubagio® 7 or 14 mg 1/day, oral
Inhibits dihydroorotate dehydrogenase, T,
B cells and IFN-γ secreting T cells
Fingolimod Glenya® 0.5 mg 1/day, oral
Antagonist of SIP receptor Decrease T,
B cells activates SIP signaling in CNS
Mitoxantrone Novatrone® 12 mg/m2
1/3 months up to
2 years
Suppresses T, B cells and macrophages.
Reduces Th1 cytokines
Dalfampridine Ampyra® 10 mg 2/day, oral
Potassium channel blocker Improves
motor symptoms, i.e., walking
Humanized Monoclonal Antibody Treatments
Natalizumab Tysabr® 300 mg 1/28 days, i.v
Humanized anti-α4-integrin Mab. Affects
cell migration, division, growth
and survival
Ofatumumab Arzerra® 3–700 mg 1/2 weeks, i.v
Humanized anti-CD20 Mab. Cytotoxic to
CD20+ cells via CDC and ADCC
Ocrelizumab Ocrevus® 300–600 mg
300 mg weeks 1
and 3, then 600 mg
1/6 months, i.v
Humanized anti-CD20 Mab
Alemtuzumab Lemtrada® 12 mg
5 days in a row;
after 1 year, 3 days
Humanized anti-CD52 Mab. Depletes T,
B cells, increases Treg, Th2, decrease
Th1 cells
Daclizumab Zinbryta® 150 mg 1/month, s.c
Humanized anti-CD25 Mab.Blocks IL-2R,
decreases T cells, increases NK cells
ADCC, antibody-dependent cellular cytotoxicity; CDC, complement-dependent cytotoxicity; DC, dendritic cells;
EKAY, single amino acid code for L-glutamic acid, lysine, alanine, tyrosine; IFN, interferon; IL-2R, interleukin-2
receptor; i.m, intramuscular; i.v, intravenous; Mab, monoclonal antibodies; NK, natural killer cells; pegIFN,
polyethylene glycol linked to IFN; pMHC, peptide-major histocompatibility complex; RRMS, relapsing remitting
multiple sclerosis; s.c, subcutaneous; SIP, sphingosine-1-phosphate; Th, helper T cells; Treg, regulatory T cells
(CD4+CD25+FoxP3+).
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3.1. Treatment of MS Relapses
Patients with MS who present with a relapse are generally treated with corticosteroids
intravenously, plasma exchange or adrenocorticotropic hormone injections [50,93]. Although
effective in reducing the duration of the relapse and patients recovery faster there are no long-term
neuroprotective benefits [27,94–97].
3.2. Long-Term Treatment of MS with Disease-Modifying Agents
The treatment of MS has been a challenge with treatment options being limited mainly to
corticosteroids, the potent alkylating agent cyclophosphamide and potent immunosuppressant
methotrexate (Table 1, Figure 2). However, with the advent of immunomodulatory drugs in mid-1990s,
a big shift was carried to treatment options for the first time [50]. The first disease-modifying drug for
RRMS, interferon beta-1(IFNβ-1) was the primary key breakthrough for the treatment of MS [98,99].
Disease-modifying agents intend to modify the course of the disease rather than improving symptoms.
Until the approval of the first oral treatment in 2010 [11], all MS treatments c nsist d of either
intramuscular or su cutaneous injectable drugs. To date, 13 FDA approved disease-modifying drugs
are available for RRMS, and several more agents are in different developmental stages [9,11,65,66,69].
In the last 20 years there has been an evolving trend in novel treatments for MS and the global
progress of therapies for MS has been quite promising. In general treatments consist of Ampyra®,
Aubagio®, Avonex®, Betaseron®, Copaxone®, Extavia®, Gilenya®, Lemtra a®, Nova trone®,
Plegridy®, Rebif®, Tecfidera® and Tysabri® [100]. Such treatment options consist of alemtuzumab
(depletes lymphocytes), daclizumab (blocks the cytokine receptor IL-2), dimethylfumarate (combines
features of immunomodulatory and immunosuppressive actions), fingolimod (modulates the
sphingosine-receptor system), natalizumab (inhibits the migration of lymphocytes) and teriflunomide
(inhibits activated T and B cells) [9,27,50]. Examples of current interferons include, Schering AG’s
Betaferon/Betaseron (IFNβ-1b), Biogen’s Avonex (IFNβ-1a) and Serono/Pfizer’s Rebif (IFNβ-1a).
In addition, immune modulating agents include, Teva’s Copaxone® (copolymer glatiramer acetate),
Amgen/Serono’s (Novantrone®; mitoxantrone), azathioprine, cyclophosphamide (Endoxan®) and
Natalizumab® an a4-integrin antagonist [101–103]. Disease-modifying agents have commonly been
shown to reduce the rate of relapses, reduce MRI lesions and stabilize or delay MS disability.
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The key therapeutic features of disease-modifying drugs are their anti-inflammatory effects in the
relapsing phase of MS, although demyelination leading to chronic disability still remains a major
hurdle [27,104–106]. Some studies, however, have shown that early intervention of disease-modifying
drugs to patients with RRMS can reduce acute disability or death [27,107–110].
In general, disease-modifying drugs main action is by suppressing or altering the immune system.
Hence, based on this theory that MS is, at least in part, a result of altered or abnormal immune response
that results in attack of the myelin sheath. Current available drugs and their actions are described
below (Table 1, Figure 2).
3.2.1. Interferons (Avonex®, Biogen, Cambridge, MA, USA; Betaseron®, Bayer, Leverkusen, Germany;
Extavia®, Novartis Pharma AG, Basel, Switzerland; Rebif®, EMD Serono Inc., Darmstadt, Germany;
Plegridy®, Biogen, Cambridge, MA, USA)
Interferon (IFN) type 1 consist of a group of IFNs (IFN-α, -β, -ε, -κ, -τ, -δ, -ζ, -ω, -ν) which help
regulate the immune system. IFN-β is primarily produced by fibroblasts but other cells such as NK
cells, B cells, T cells, macrophages also secrete IFN-β. IFN-β has anti-viral and anti-tumor activity as
well as being effective in reducing the relapse rate in patients with MS [106]. The mechanism by which
IFN-β acts, is that it balances the expression of pro- and anti-inflammatory cytokines in the brain and
decreases the number of inflammatory cells crossing the blood brain barrier. As a consequence, there
is decreased inflammation of neurons, increases nerve growth factors and improves neuronal survival.
Moreover, IFN-β reduces Th17 population and IL-17 cytokine which are known to be involved in the
immunopathophysiology of MS [111]. IFN-β injection subcutaneously or intramuscularly to patients
with RRMS aims to decrease the relapse rate, duration and severity, however, there is lack of efficacy
to long-term disability. Avonex was approved in 1996, the first FDA approved treatment for RRMS.
To date there are 3 approaches using IFN-β; IFN-β1a low dosage (Avonex®), IFN-β1a (Rebif®) high
dosage, and, IFN-β1b (Betaseron®, Extavia®) high dosage. Furthermore, pegIFN-β-1a (Plegridy®) has
polyethylene glycol linked to IFN-β-1a allowing it to be active for longer in the body, hence fewer
injections are required compared to Avonex®, Rebif®, Betaseron® and Extavia®. The first large scale
human clinical trial in patients with RRMS using IFN-βwas published in 1993 and showed that relapse
rates were reduced by 34% in high dose IFN-β1b and by 8% in lower dose compared to placebo
group and severity of relapses were also reduced [112]. Subsequent 5 year follow-up data showed
that IFN-β1a and IFN-β1b decreased lesions up to 30% and reduced the formation of new lesions up
to 50%, however, the study failed to show any reduction in disability progression in patients [113].
IFNs have no direct neuroprotective effects, however, through their direct effect on CD4+Th1 cells and
altering their profile results in decreased demyelination of neurons, which prevents further neuronal
damage [114]. Despite the impact of IFN-β in disease progression in patients with RRMS there are
limitations in their use, with side effects ranging from local body aches, skin reactions (swelling,
redness), fever, myalgia, flu-like symptoms to more serious side effects such as suicidal thoughts,
hallucinations, seizures and heart and liver problems [9]. As a result, many patients have stopped
treatment and overall the benefit of using IFNs is relatively small.
3.2.2. Glatiramer Acetate (Copaxone®, Inc., Petah Tikva, Israel)
Glatiramer acetate (GA) is a synthetic 4-mer peptide (L-glutamic acid, lysine, alanine, and tyrosine)
mimic of MBP, which competes with short antigenic MBP peptides in complex with MHC class II.
Initially, GA was designed to induce EAE but instead it suppressed EAE, which was quickly translated
into human trials with MS in order to prevent disease progression, as it bound to MHC class II and
inhibited the activation of encephalitogenic T cells [115–118]. GA diverts Th1 cells to Th2 cells that
suppress inflammatory responses and activate Tregs in the periphery [119]. In patients, GA significantly
reduced disease symptoms and development of new lesions by up to 30% in RRMS, although it showed
no improvement in long-term efficacy on progression of disability [120]. GA injection in patients
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results in side effects ranging from minor (fever, chills) to more serious (cardiovascular, digestive,
muscular, respiratory issues).
3.2.3. Dimethyl Fumarate (Tecfidera®, Biogen, Cambridge, MA, USA)
Dimethyl fumarate (BG-12) is a methyl ester of fumaric acid that modulates immune responses
and was approved by the FDA in 2013. BG-12 was shown in phase III clinical trials to reduce relapse
rate and increase the time to disability progression in patients with RRMS [121]. BG-12 reduces
the migration of inflammatory cells through the blood brain barrier and activates nuclear factor
erythroid 2-related factor (Nrf2) [122]. Nrf2 regulates anti-oxidative proteins that protect cells against
oxidative damage and inflammation. In fact, BG-12 protects neuronal cells from oxidative stress
by increasing glutathione levels and suppressing pro-inflammatory cytokines from splenocytes
in vitro [123]. Side effects of BG-12 include diarrhea, abdominal pain, nausea, abnormal liver enzymes
and decreased lymphocyte counts.
3.2.4. Teriflunomide (Aubagio®, Sanofi Genzyme, Cambridge, MA, USA)
Teriflunomide is an active metabolite of leflunomide (an immunosuppressive disease-modifying
drug used for rheumatoid arthritis) which inhibits the enzyme dihydroorotate dehydrogenase [124]
and inhibits the proliferation of B and T cells. In addition, teriflunomide exerts anti-inflammatory
properties by inhibiting IFN-gamma producing T cells while IL-4 and IL-10 producing T cells are
unaffected [125]. In MS, oral administration of teriflunomide reduced relapse rates, MS lesions and
decreased disability progression [126–131]. Moreover, permanent discontinuation due to side effects
was substantially less common in MS patients who received teriflunomide compared to IFN-β-1a. Side
effects include, reduced white blood cell count, alopecia, hepatic effects, nausea, diarrhea, numbness
in hand and feet, allergic reactions, breathing issues and increased blood pressure. Teriflunomide was
approved by the FDA in 2012 and by EMA in 2013 for use in patients with RRMS.
3.2.5. Fingolimod (Gilenya®, FTY720, Novartis Pharma AG, Basel, Switzerland)
Fingolimod was granted FDA approval in 2010 and was the first oral therapy (0.5 mg once daily)
available for patients with relapsing forms of MS. Fingolimod is a sphingosine 1-phosphate (S1P)
receptor modulator, which acts as a super agonist of S1P receptor causing receptor internalization
and leading to reduced infiltration of potentially auto-reactive lymphocytes into the CNS, and as
such, they remain localized in the lymph nodes [132–134]. In addition, a secondary beneficial
effects of fingolimod is that it targets SIP receptors on glia cells in the CNS, activating signaling
pathways within the CNS [132,135]. Based on Phase III human clinical trials in patients with RRMS
(TRANSFORMS, FREEDOMS and FREEDOMS II), fingolimod was more effective compared to first
line treatment IFNβ-1a and placebo, in reducing the frequency of flare-ups (clinical exacerbations),
disability progression, MRI outcome measures, including brain volume loss and was associated with
clearly identified adverse events [103,136,137]. More than 180,000 patients have been treated with
fingolimod in clinical trials and post-marketing settings globally, and the total patient exposure now
exceeds 395,000 patient-years. Side effects include bradycardia (within 6 h after treatment initiation),
blurred vision, diarrhea, back pain, headache, cough and vomiting. With reasonable data showing its
long-term safety and disease improvement, fingolimod is a great alternative choice for patients with
highly active RRMS and who prefer the oral treatment option.
3.2.6. Mitoxantrone (Novantrone®, Immunex/Amgen, Thousand Oaks, CA, USA)
Mitoxantrone is primarily used to treat certain types of cancers, in particular, non-Hodgkin’s
lymphoma, acute myeloid leukemia, breast and prostate cancer. Mitoxantrone is a type-II
topoisomerase inhibitor, which disrupts DNA synthesis and DNA repair of cancer cells, however,
normal cells are also affected. It is a potent immune suppressant, suppressing T cells, B cells and
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macrophages and reduces pro-inflammatory cytokines (IFN-γ, TNF-α, and IL-2) [138,139]. In patients
with SPMS, intravenous injection of 12 mg/m2 mitoxantrone every 3 months up to 2 years resulted
in reduced disability progression by 84% [140,141]. However, several side effects are associated with
mitoxantrone which range from nausea, vomiting, hair loss, to, cardiotoxicity, leukemia, infertility,
infection, leukopenia and thrombocytopenia [11]. As a result, its use has significantly been reduced
over time. Furthermore, due to the risk of cardiotoxicity and leukemia, there is a limit on the cumulative
lifetime dose to be administered to patients [11,142].
3.3. Treatment Using Humanized Monoclonal Antibodies
3.3.1. Natalizumab (Tysabr®, Biogen, Cambridge, MA, USA)
Natalizumab is a humanized monoclonal antibody against the cellular adhesion molecule
α4- integrin. Integrins are transmembrane receptors that enable cell-extracellular matrix adhesion
activating cell signaling which regulate cell growth, division, survival, differentiation and migration.
Integrins are expressed on T cells, B cells, monocytes, macrophages, NK cells, DC, neutrophils and
eosinophils. Interfering or blocking α4-integrin affects immune cell migration across the blood brain
barrier, thus, by blocking the interaction between α4-integrin and vascular endothelial adhesion
molecule-1, inhibits transendothelial migration to the CNS [143]. Natalizumab is administered
intravenously once a month [144] which reduces activated T cells within the CNS, resulting in
anti-inflammatory responses and hence, neuroprotective effects [114]. In a phase III clinical trial
natalizumab reduced brain lesions and the rate of disability progression up to 24 months [12,145].
In addition, natalizumab decreased by 92% of contrast-enhancing lesions, by 83% of new or expanding
T2-weighted lesions, and by 76% in new T1-weighted hypointense lesions [146,147]. Natalizumab,
was approved by the FDA in 2004, but was withdrawn due to 3 cases of rare brain infection, progressive
multifocal leukoencephalopathy (PML; that usually leads to death or severe disability), but was
re-introduced in 2006 under a special prescription program. However, by 2012 a further 212 cases
(or 2.1/1000) of PML were reported to be attributed to natalizumab [148]. Despite these reports the FDA
has not withdrawn natalizumab from the market as the clinical benefits outweigh the risks involved.
Other side effects include, hepatotoxicity, allergic reactions and increased risks of infection. Due to the
risks involved with natalizumab, there are reservations over its use as a preferred treatment option.
3.3.2. Ofatumumab (Arzerra®, Novartis Pharma AG, Basel, Switzerland)
Ofatumumab (OMB157) is the first fully human type 1 IgG1 kappa (IgG1κ) monoclonal
antibody and is currently licensed for the treatment (of patients with chronic lymphocytic leukemia
(intravenously (iv), Arzerra®). It has also been shown to be beneficial to patients with rheumatoid
arthritis, follicular non-Hodgkin’s lymphoma, diffuse B cell lymphoma and MS. B cells play a role in
the pathogenesis of MS. B cells have essential functions in regulating immune response, by activating
CD4+ T-cells and regulating T-cell responses via the secretion of cytokines and antibodies. B cells
are present at demyelinating areas and in cerebrospinal fluid of patients with MS [149]. CD20 is
a marker and present on the cell surface of all B cells. In an attempt to reduce the number of B
cells including autoreactive B cells, the use of anti-CD20 antibodies would conceivably improve
MS relapses and progression. In fact, there are several humanized anti-CD20 antibodies, such as
rituximab [150], ocrelizumab [151] and ofatumumab [152], which have shown high efficacy in patients
with RRMS. In 2015, Novartis acquired the rights from GlaxoSmithKline for the development of
ofatumumab in oncology and other autoimmune indications. Ofatumumab binds to 2 unique novel
epitopes on the CD20 molecule, induces B-cell depletion via complement dependent cytotoxicity
and antibody-dependent cell-mediated cytotoxicity causing B cell apoptosis [153]. Ofatumumab has
demonstrated high efficacy in hematologic malignancies and in rheumatoid arthritis. Based on 2 Phase
II dosing human clinical studies, ofatumumab demonstrated high efficacy in reducing new MRI lesion
activity more than 90% and was well tolerated in patients with MS [152]. Currently, ofatumumab is
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being further investigated in 2 Phase III trials (ASCLEPIOS I AND ASCLEPIOS II) and are recruiting
patients with relapsing forms of MS (ofatumumab versus teriflunomide). The adaptive study design of
both trials was recently presented by Hauser SL and colleagues at the American Academy of Neurology
April 2017 in Boston, USA and results are highly anticipated [154].
3.3.3. Ocrelizumab (Ocrevus®, Genentech Inc., San Fransisco, CA, USA)
A few months ago (March 2017), the FDA approved ocrelizumab to be used in PPMS, the first
drug approved by the FDA for this form of MS and phase IV clinical trials were a requirement of the
FDA to be conducted in order to determine the safety of ocrelizumab in younger patients with MS,
ie, risk of cancer and effects on pregnancy (study outcomes due by 2024); although clinical trials in
patients with lupus and rheumatoid arthritis were halted due to high rates of infections and increased
risk of progressive multifocal leukoencephalopathy [155]. In addition, in patients with MS, there was
an increased risk of breast cancer (6/781 females with MS on ocrelizumab compared to 0/668 females
with MS in other trials) [155].
3.3.4. Alemtuzumab (Lemtrada®, Sanofi Genzyme, Cambridge, MA, USA)
Alemtuzumab is a humanized monoclonal antibody against CD52, a cell surface molecule
expressed on B and T cells; mature NK cells, plasma cells, neutrophils and importantly, hematological
stem cells do not express CD52. In phase III clinical trials in patients with RRMS, alemtuzumab
showed significantly lower annualized relapse rates and MRI measures (gadolinium-enhancing lesions,
new or enlarging T2 lesions and brain atrophy) and were free of clinical disease longer, compared to
IFNβ-1a [156,157]. Alemtuzumab can cause serious side effects including, immune thrombocytopenia,
kidney problems, serious infusion problems (trouble breathing, swelling, chest pain, irregular heart
beat), certain cancers (blood cancers, thyroid cancer), cytopenia and serious infections. It was approved
by the FDA in 2014 to be used in RRMS patients, but due to the frequent and significant adverse events
of alemtuzumab, it is generally used in patients with RRMS who have used 2 or more MS drugs and
have failed to work.
3.3.5. Daclizumab (Zinbryta®, Biogen, Cambridge, MA, USA)
Daclizumab is a humanized monoclonal antibody against CD25, the IL-2 receptor expressed on
the surface of T cells. The mechanism by which daclizumab works is that it blocks the IL-2 receptor on
T cells, preventing the activation of T cells. It was originally approved by the FDA in 1997 to prevent
acute kidney transplants (together with corticosteroids and cyclosporine) however its use was halted
due to low market demand. In recent years its use has re-emerged to treat patients with RRMS, it is
injected subcutaneously, once a month [158]. In human clinical trials, daclizumab showed 45% reduced
annualized relapse rates and 54% lower in the number of new lesions [158]. The side effects associated
with daclizumab are relatively minor compared to other MS drugs, and include infections, skin rashes
and liver complications.
4. New and Emerging Immunotherapeutic Strategies against MS
Antigen/peptide specific immunotherapy or using immune cells (i.e., stems cells), aim to restore
tolerance while avoiding the use of non-specific immunosuppressive drugs as describe in Section 3,
is a promising approach to fight autoimmune diseases including MS. As such, a number of approaches
have been utilized.
4.1. Stem Cells
Multipotent hematopoietic stem cells (HSC) are cells isolated either from the bone marrow,
umbilical cord blood or peripheral blood and are transplanted into the recipient. More commonly used
for hematological malignancies (leukemia, multiple myeloma) its application has also expanded into
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autoimmune diseases. The first report of a bone marrow transplant in 1997 in a chronic myelogenous
leukemia patient with MS which showed marked improvements in MS brain lesions [159] quickly led
to the use of HSC transplantation (HSCT) in MS patients. HSCT in patients with active RRMS, reduce
progression in about 70% of patients, decrease relapses dramatically and suppresses inflammatory
MRI activity [160]. MS patients who have not responded to conventional therapy, who’s disease is
aggressive with relapsing-remitting course and who are not presenting with high level of disability,
are considered appropriate candidates for such treatment [161]. Although the clinical efficacy of HSCT
long term has not been established. The mechanism by which HSCT works is that HSCT “reboots” the
immune system and thus, prevents inflammation associated with the disease.
Mesenchymal stem cells (MSC) are isolated from an adult’s bone marrow, are differentiated
in vitro for 2–3 weeks and re-injected back into the patient. In recent years a vast amount of research
has been conducted in MSCs to treat MS with most studies being in mice and EAE models, and more
recently in human clinical trials. In fact, in a pilot study in advanced MS patients, MSC transplantation
improved expanded disability scale score with stabilization in 1/7 and disease progression in 1/7
patients and vision and low contrast sensitivity test showed improvement in 5/6 patients with 1/6
showing worsening effects [162]. In a phase II randomized double-blind, placebo-controlled crossover
clinical trial showed lower mean cumulative number of lesions in patients receiving MSCs compared
to placebo [163]. No serious adverse events were reported. The mechanism of action of MSC includes
immunomodulation, neuroprotection and neuroregeneration [162]. The use of MSCs that reduce MRI
parameters is a new and emerging research focus to develop new improved treatments for MS.
4.2. DNA Vaccine Studies
BHT-3009, a DNA vaccine that encodes the full-length human MBP, was developed with the
aim to tolerize patients with MS against MBP [9,164,165]. In fact, in 30 patients with RRMS or SPMS
who received 4 injections of BHT-3009 on weeks 1, 3, 5, 9 with escalating doses of 0.5 mg, 1.5 mg or
3 mg was reported to be safe and conferred positive changes on brain MRI and reduced the number
of CD4+ T cells [9,164,166]. In addition, in a retrospective, randomized double blind, phase II study
in 155 MS patients, BHT-3009 had no impact on the risk for persistent black holes (axonal loss and
disability progression). However, there was a correlation to those who had generated high anti-IgM
MBP antibodies to reduced risk of persistent black holes [167].
4.3. Nanoparticles
Nanoparticles have extensively been characterized and used as vaccine formulations in pre-clinical
models of cancer and infectious diseases [168,169]. Polymeric biodegradable lactic-glycolic acid
(PLGA) nanoparticles loaded with MOG35–55 peptide together with recombinant IL-10, were partially
endocytozed by dendritic cells, secreted both MOG35–55 peptide and IL-10 in culture media for several
weeks in vitro [170]. In mice, PLGA nanoparticles (MOG35–55 + IL-10) showed significant amelioration
of EAE and reduction of IL-17 and IFN-gamma secretion by splenic T cells in vitro [170]. Recently,
poly(ε-caprolactone) nanoparticles loaded with recombinant human MBP reduced IFN-gamma
cytokines, reduced the clinical score and showed only mild histological changes of the myelin
sheath [171]. Hence, nanoparticles as a delivery method of self-antigens are a promising tool to
treat MS.
4.4. Altered Peptide Ligands
Altered peptide ligands (APL) are peptides closely related to the native (agonist) peptide with
defined 1–2 substituted amino acid residues which interact with the T cell receptor (TCR) yet retains
its binding ability to the MHC [65]. In phase I/II clinical trial by Neurocrine Biosciences Inc, used
an APL of MBP83−99, where L-amino acids were changed to D-amino acids at positions 83, 84, 89, 91
(NBI-5788) [172]. However, this mode of APL induced T cell cross reactivity between the APL and the
wild-type/agonist MBP83−99 peptide and adverse events in some patients resulted [173]. A subsequent
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multi-center double-blinded phase II clinical trial with NBI-5788 was suspended—Th2 responses were
induced (IL-5, IL-13), however, 13/142 patients developed immediate-type hypersensitivity, who also
generated anti-NBI-5788 antibodies which cross-reacted with native agonist MBP83–99 peptide [172,174].
National Institute of Neurological Disorders and Stroke sponsored trial, CGP77116, was used in a
MRI-controlled phase II clinical trial. CGP77116, has Ala D-amino acids of MBP83–99 peptide at
positions 83, 84, 89, 91 (CGP77116) of MBP83–99 peptide, in order to enhance stability [174]. However,
this peptide was poorly tolerated at the dose tested, and the trial had to be discontinued. Three
patients showed exacerbations to disease of which two were linked to CGP77116 injection with high
IFN-gamma and low IL-4 (Th1-skewing) were secreted by activated CD4+ T cells. These CD4+ T cells
also cross reacted with the native agonist MBP83–99 peptide [175]. Accordingly, the problems noted
with both NBI-5788 and CGP77116 were likely due to inadequate pre-screening of APL effects on
the many clonotypes against the targeted epitopes. Thus, although the APL was highly effective at
blocking or switching some clones, it activated others. Thus, further pre-clinical testing is required and
new modified peptides need to be designed, or a carrier needs to be used which further changes the
resulting immune response.
4.4.1. Cyclic Peptides
Cyclization of peptides increases the stability, since linear peptides are sensitive to proteolytic
enzymes. In addition, cyclic peptides are an important intermediate step and a useful template towards
the rational design and development of non-peptide mimetics. While mimetic strategy is a challenging
perspective it is worth pursuing in particular for MBP epitope-based MS therapy as it is still in its
infancy. Efforts to design semi-mimetics of MBP72–85 epitope by combining non-natural amino acids
as spacers and MBP epitope immunophores (Ser, Arg, Glu, Ala, Gln), led to substances that were
effective to some extent in inducing the onset of EAE. Cyclic peptides are not only as a step towards
non-peptide mimetics but also as putative therapeutics in MS [66].
Structure activity studies of the immunodominant agonist peptide MBP87–99, have shown that
K91, P96 are important T cell receptor contact residues. Double mutation of K91, P96 to R91,A96 or
single mutation of P96 to A96 (APL) of either in their linear or cyclic forms, results in suppression
of EAE and decreased inflammation in the spinal cord of Lewis rats [71]. Single and double
cyclic[A91]MBP83–99 peptide and cyclic[A91A96]MBP83–99 peptides emulsified in CFA induced IL-4
cytokines in SJL/J mice [62] however conjugation to reduced mannan further enhanced IL-4 cytokines
with no IFN-gamma responses [63]. In guinea pigs and Lewis rats, cyclic[A91A96]MBP83–99 showed
significantly reduced mechanical pain hypersensitivity compared to cyclic MBP83–99 peptide. This was
associated with reduced T cell and macrophage infiltration to injured nerves of the spinal cord of
animals [176–178]. In addition, these APL decreased CD4+ T cell line proliferation raised from a patient
with MS, increased IL-10 cytokine secretion, bound to HLA-DR4 and were more stable to lysosomal
enzymes (cathepsin B, D, H) compared to their linear counterparts [70]. Double mutation of K91, P96 to
A91, A96 in either linear or cyclic forms were also shown to be active, with suppression of EAE in
SJL/J mice, higher Th2 over Th1 cytokines produced, bound to HLA-DR4, the cyclic forms were more
stable to lysosomal enzymes and induced high levels of IL-10 of peripheral blood mononuclear cells
from patients with MS [61]. Recently, cyclic native agonist MOG35–55 peptide was shown to ameliorate
clinical and neuropathological features of EAE in mice compared to its linear counterpart [179]. Thus,
cyclic peptides, which offer greater stability and are able to modulate immune responses, are novel
leads for the immunotherapy of many diseases, such as MS [66].
4.4.2. Mannan as a Carrier to Modulate Immune Responses
Mannan, a polymannose, isolated from the wall of yeast cells has been shown to bind to
the mannose receptor on dendritic cells as well as being a ligand for toll-like receptor 4 [180,181].
Mannan conjugated to MUC1 cancer protein induces immune responses in mice and protects mice
against tumor challenge. This work was translated into human phase I, II and pilot III clinical
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trials; mannan-MUC1 induces protection against cancer recurrence at 18 years follow-up [182–185].
Furthermore, ex vivo cultured dendritic cells pulsed with mannan-MUC1 (CVacTM) and re-injection
into patients induces strong cellular and clinical responses in ovarian cancer patients [186,187]. Due to
the immunomodulatory properties of mannan, its effects as a carrier to MS peptides were determined.
Mutations of MBP83–99 agonist native peptide to result in mutant peptides (APL)—linear
[A91]MBP83–99, [E91]MBP83–99, [F91]MBP83–99, [Y91]MBP83–99 and [R91, A96]MBP83–99, induced
IFN-gamma albeit reduced compared to the native agonist peptide, however, only the double
APL [R91, A96]MBP83–99 induced IL-4 secretion by T cells and antagonized IFN-gamma production
in vitro by T cells against the native MBP83–99 peptide [67]. In addition, T cells against the native
MBP83–99 peptide cross-reacted with all peptides except [Y91]MBP83–99 and [R91,A96]MBP83–99 [68].
Conjugation of [R91,A96]MBP83–99, [A91,A96]MBP83–99, F91]MBP83–99, [Y91]MBP83–99 peptides to
mannan, completed abrogated IFN-gamma responses and elicited high IL-4 (i.e., Th1 to Th2
switch) [63,69,188]. Likewise, linear double-mutant APL [L144R147]PLP139–151 induces high levels
of IL-4, and cyclization of this analog elicited low levels of IFN-gamma. When conjugated to mannan,
[L144R147]PLP139–151 peptide completely abrogated IFN-gamma, while both linear and cyclic native
agonist PLP139–151 peptides stimulated IFN-gamma secreting T cells [64]. Furthermore, mannan
conjugated to the immunodominant agonist MOG35–55 peptide primes non-pathogenic Th1 and Th17
cells and ameliorates EAE in mice [73]; a phase I human clinical trial is planned using mannan
conjugated to MOG35–55 peptide later this year. It is clear that, mannan is able to divert immune
responses from Th1 to Th2 and is a promising carrier for further studies for the development of
immunotherapeutics against MS.
5. Symptomatic Medication
Dalfampridine (Ampyra/Fampyra®, Acorda Therapeutics)
Dalfampridine is not intended to delay symptoms or change the course of disease, but rather,
to improve motor symptoms such as walking. Dalfampridine, is a potassium channel blocker, resulting
in improved potassium currents and nerve conductance. Dalfampridine is used in patients who have
had MS for more than 3 years and it was approved by the FDA in 2010. Common side effects include
nausea, nervousness and dizziness, which are relatively minor compared to other MS drugs.
6. Conclusions and Future Prospects
MS is an autoimmune disorder of the CNS with an array of immune cells being either activated
or suppressed leading to demyelination and disease progression. In addition, genetic predisposition,
viral mimicry, vitamin and mineral deficiency, geographical location are also etiological factors that
contribute to disease. More recently, citrulination of myelin peptides have been shown to contribute to
disease activation [59,60]. A number of treatment options are available to patients with MS, in particular
those with active disease, however due to side effects, limited long term effectiveness and inability to
reverse disease, new improved treatment options are required. As described here a number of new
and upcoming promising therapeutic candidates are becoming available, although their effectiveness
in human clinical trials remains to be determined. Recently, it was reported that non-peptide mimetics
mapping the MBP83–96 T cell epitope can function as T cell receptor antagonists, hence such an approach
may pave the way to developing alternative and improved immunotherapeutics against MS [189].
With the plethora of information regarding the immunopathophysiology of MS and availability of
treatment options and new upcoming treatments, the future holds promise for managing and treating
the disease.
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